Marko Fonović1, Boris Turk2. 1. Department of Biochemistry, Molecular and Structural Biology, Jozef Stefan Institute, Jamova cesta 39, SI-1000 Ljubljana, Slovenia; Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, Jamova cesta 39, SI-1000 Ljubljana, Slovenia. Electronic address: marko.fonovic@ijs.si. 2. Department of Biochemistry, Molecular and Structural Biology, Jozef Stefan Institute, Jamova cesta 39, SI-1000 Ljubljana, Slovenia; Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, Jamova cesta 39, SI-1000 Ljubljana, Slovenia; Faculty of Chemistry and Chemical Technology, University of Ljubljana, Slovenia. Electronic address: boris.turk@ijs.si.
Abstract
BACKGROUND: Cysteine cathepsins are normally found in the lysosomes where they are involved in intracellular protein turnover. Their ability to degrade the components of the extracellular matrix in vitro was first reported more than 25years ago. However, cathepsins were for a long time not considered to be among the major players in ECM degradation in vivo. During the last decade it has, however, become evident that abundant secretion of cysteine cathepsins into extracellular milieu is accompanying numerous physiological and disease conditions, enabling the cathepsins to degrade extracellular proteins. SCOPE OF VIEW: In this review we will focus on cysteine cathepsins and their extracellular functions linked with ECM degradation, including regulation of their activity, which is often enhanced by acidification of the extracellular microenvironment, such as found in the bone resorption lacunae or tumor microenvironment. We will further discuss the ECM substrates of cathepsins with a focus on collagen and elastin, including the importance of that for pathologies. Finally, we will overview the current status of cathepsin inhibitors in clinical development for treatment of ECM-linked diseases, in particular osteoporosis. MAJOR CONCLUSIONS: Cysteine cathepsins are among the major proteases involved in ECM remodeling, and their role is not limited to degradation only. Deregulation of their activity is linked with numerous ECM-linked diseases and they are now validated targets in a number of them. Cathepsins S and K are the most attractive targets, especially cathepsin K as a major therapeutic target for osteoporosis with drugs targeting it in advanced clinical trials. GENERAL SIGNIFICANCE: Due to their major role in ECM remodeling cysteine cathepsins have emerged as an important group of therapeutic targets for a number of ECM-related diseases, including, osteoporosis, cancer and cardiovascular diseases. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
BACKGROUND: Cysteine cathepsins are normally found in the lysosomes where they are involved in intracellular protein turnover. Their ability to degrade the components of the extracellular matrix in vitro was first reported more than 25years ago. However, cathepsins were for a long time not considered to be among the major players in ECM degradation in vivo. During the last decade it has, however, become evident that abundant secretion of cysteine cathepsins into extracellular milieu is accompanying numerous physiological and disease conditions, enabling the cathepsins to degrade extracellular proteins. SCOPE OF VIEW: In this review we will focus on cysteine cathepsins and their extracellular functions linked with ECM degradation, including regulation of their activity, which is often enhanced by acidification of the extracellular microenvironment, such as found in the bone resorption lacunae or tumor microenvironment. We will further discuss the ECM substrates of cathepsins with a focus on collagen and elastin, including the importance of that for pathologies. Finally, we will overview the current status of cathepsin inhibitors in clinical development for treatment of ECM-linked diseases, in particular osteoporosis. MAJOR CONCLUSIONS: Cysteine cathepsins are among the major proteases involved in ECM remodeling, and their role is not limited to degradation only. Deregulation of their activity is linked with numerous ECM-linked diseases and they are now validated targets in a number of them. Cathepsins S and K are the most attractive targets, especially cathepsin K as a major therapeutic target for osteoporosis with drugs targeting it in advanced clinical trials. GENERAL SIGNIFICANCE: Due to their major role in ECM remodeling cysteine cathepsins have emerged as an important group of therapeutic targets for a number of ECM-related diseases, including, osteoporosis, cancer and cardiovascular diseases. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.
Authors: Barbara Sobotič; Matej Vizovišek; Robert Vidmar; Petra Van Damme; Vasilena Gocheva; Johanna A Joyce; Kris Gevaert; Vito Turk; Boris Turk; Marko Fonović Journal: Mol Cell Proteomics Date: 2015-06-16 Impact factor: 5.911
Authors: Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton Journal: J Control Release Date: 2018-08-09 Impact factor: 9.776
Authors: Erica N Parker; Jiangli Song; G D Kishore Kumar; Samuel O Odutola; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Tracy E Strecker; Ashleigh L Barnes; Dhivya R Sudhan; Thomas R Wittenborn; Dietmar W Siemann; Michael R Horsman; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney Journal: Bioorg Med Chem Date: 2015-09-25 Impact factor: 3.641
Authors: Yu Cao; Xing Liu; Ying Li; Yao Lu; Hua Zhong; Weihong Jiang; Alex F Chen; Timothy R Billiar; Hong Yuan; Jingjing Cai Journal: Int Urol Nephrol Date: 2017-05-22 Impact factor: 2.370
Authors: Michael R Kanost; Estela L Arrese; Xiaolong Cao; Yun-Ru Chen; Sanjay Chellapilla; Marian R Goldsmith; Ewald Grosse-Wilde; David G Heckel; Nicolae Herndon; Haobo Jiang; Alexie Papanicolaou; Jiaxin Qu; Jose L Soulages; Heiko Vogel; James Walters; Robert M Waterhouse; Seung-Joon Ahn; Francisca C Almeida; Chunju An; Peshtewani Aqrawi; Anne Bretschneider; William B Bryant; Sascha Bucks; Hsu Chao; Germain Chevignon; Jayne M Christen; David F Clarke; Neal T Dittmer; Laura C F Ferguson; Spyridoula Garavelou; Karl H J Gordon; Ramesh T Gunaratna; Yi Han; Frank Hauser; Yan He; Hanna Heidel-Fischer; Ariana Hirsh; Yingxia Hu; Hongbo Jiang; Divya Kalra; Christian Klinner; Christopher König; Christie Kovar; Ashley R Kroll; Suyog S Kuwar; Sandy L Lee; Rüdiger Lehman; Kai Li; Zhaofei Li; Hanquan Liang; Shanna Lovelace; Zhiqiang Lu; Jennifer H Mansfield; Kyle J McCulloch; Tittu Mathew; Brian Morton; Donna M Muzny; David Neunemann; Fiona Ongeri; Yannick Pauchet; Ling-Ling Pu; Ioannis Pyrousis; Xiang-Jun Rao; Amanda Redding; Charles Roesel; Alejandro Sanchez-Gracia; Sarah Schaack; Aditi Shukla; Guillaume Tetreau; Yang Wang; Guang-Hua Xiong; Walther Traut; Tom K Walsh; Kim C Worley; Di Wu; Wenbi Wu; Yuan-Qing Wu; Xiufeng Zhang; Zhen Zou; Hannah Zucker; Adriana D Briscoe; Thorsten Burmester; Rollie J Clem; René Feyereisen; Cornelis J P Grimmelikhuijzen; Stavros J Hamodrakas; Bill S Hansson; Elisabeth Huguet; Lars S Jermiin; Que Lan; Herman K Lehman; Marce Lorenzen; Hans Merzendorfer; Ioannis Michalopoulos; David B Morton; Subbaratnam Muthukrishnan; John G Oakeshott; Will Palmer; Yoonseong Park; A Lorena Passarelli; Julio Rozas; Lawrence M Schwartz; Wendy Smith; Agnes Southgate; Andreas Vilcinskas; Richard Vogt; Ping Wang; John Werren; Xiao-Qiang Yu; Jing-Jiang Zhou; Susan J Brown; Steven E Scherer; Stephen Richards; Gary W Blissard Journal: Insect Biochem Mol Biol Date: 2016-08-12 Impact factor: 4.714